Walleye Capital LLC lessened its holdings in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Rating) by 32.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,000 shares of the company’s stock after selling 8,196 shares during the period. Walleye Capital LLC’s holdings in Edgewise Therapeutics were worth $135,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Amalgamated Bank bought a new position in shares of Edgewise Therapeutics during the 1st quarter valued at about $61,000. SG Americas Securities LLC bought a new position in shares of Edgewise Therapeutics during the 2nd quarter valued at about $90,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Edgewise Therapeutics during the 2nd quarter valued at about $96,000. Dynamic Technology Lab Private Ltd bought a new stake in Edgewise Therapeutics in the 1st quarter valued at approximately $125,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in Edgewise Therapeutics in the 2nd quarter valued at approximately $175,000.
Edgewise Therapeutics Stock Up 1.4 %
Shares of Edgewise Therapeutics stock opened at $10.00 on Monday. Edgewise Therapeutics, Inc. has a 12-month low of $5.41 and a 12-month high of $22.98. The stock has a market cap of $632.14 million, a P/E ratio of -8.20 and a beta of -0.23. The business’s 50 day moving average is $9.94 and its 200-day moving average is $9.14.
Wall Street Analysts Forecast Growth
Insider Transactions at Edgewise Therapeutics
In other news, General Counsel John R. Moore sold 4,730 shares of the company’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $9.76, for a total transaction of $46,164.80. Following the sale, the general counsel now owns 3,000 shares in the company, valued at approximately $29,280. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Edgewise Therapeutics news, Director Peter A. Thompson bought 484,496 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The shares were acquired at an average cost of $10.32 per share, with a total value of $4,999,998.72. Following the acquisition, the director now owns 13,981,952 shares of the company’s stock, valued at $144,293,744.64. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, General Counsel John R. Moore sold 4,730 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $9.76, for a total value of $46,164.80. Following the transaction, the general counsel now directly owns 3,000 shares in the company, valued at $29,280. The disclosure for this sale can be found here. Company insiders own 37.05% of the company’s stock.
Edgewise Therapeutics Profile
Edgewise Therapeutics, Inc, a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
- Get a free copy of the StockNews.com research report on Edgewise Therapeutics (EWTX)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.